Nanomedicine News RSS Feed - Nanomedicine

SLAC Researchers Study Interaction between ARB Drug and Receptor at the Atomic Level

SLAC Researchers Study Interaction between ARB Drug and Receptor at the Atomic Level

An experiment at the Department of Energy's SLAC National Accelerator Laboratory has revealed in atomic detail how a hypertension drug binds to a cellular receptor that plays a key role in regulating blood pressure. The results could help scientists design new drugs that better control blood pressure while limiting side effects. [More]
Low-Cost Nanofiber Mesh for Tissue Treatment Earns Top Honors at Design Competition

Low-Cost Nanofiber Mesh for Tissue Treatment Earns Top Honors at Design Competition

Vincent Zaballa, graduate student in the Department of Biomedical Engineering at Texas A&M University, has earned top honors at a medical device design competition that evaluated the commercial potential of medical device projects. [More]
Lipid Nanoparticle siRNA Cocktail Holds Promise Against Ebola Virus Makona Infection

Lipid Nanoparticle siRNA Cocktail Holds Promise Against Ebola Virus Makona Infection

Tekmira Pharmaceuticals Corporation, an industry-leading therapeutic solutions company focused on developing a cure for chronic hepatitis B virus infection (HBV), announced today the publication of preclinical data highlighting positive results against Ebola virus Makona infection using a newly adjusted siRNA cocktail. The paper is titled, "Lipid Nanoparticle siRNA Treatment of Ebola Virus Makona-infected Nonhuman Primates," (Thi et al., Nature April 22, 2015, doi:10.1038/nature14442). [More]
Project on Bioinspired Silicate Nanocomposites for Cartilage Tissue Engineering Receives Sigma Xi GIAR

Project on Bioinspired Silicate Nanocomposites for Cartilage Tissue Engineering Receives Sigma Xi GIAR

James Carrow, graduate student in the Department of Biomedical Engineering at Texas A&M University, has been named recipient of a Sigma Xi Grant-in-Aid of Research (GIAR). [More]
Tiny Sensors with Nanoparticles to Detect Insecticides, Cancers

Tiny Sensors with Nanoparticles to Detect Insecticides, Cancers

A Case Western Reserve University researcher has won a $500,000 National Science Foundation grant to create tiny sensors capable of detecting insecticides in Lake Erie or determining subtypes of human cancers. [More]
Nanoparticle-Based Skin Ointment May Help Heal Painful Ulcers in Diabetic Patients

Nanoparticle-Based Skin Ointment May Help Heal Painful Ulcers in Diabetic Patients

A new high-tech but simple ointment applied to the skin may one day help diabetic patients heal stubborn and painful ulcers on their feet, Northwestern University researchers report. [More]
Dopamine Packaged in Biodegradable Nanoparticles Reverses Parkinson's-Like Symptoms

Dopamine Packaged in Biodegradable Nanoparticles Reverses Parkinson's-Like Symptoms

As baby boomers age, the number of people diagnosed with Parkinson's disease is expected to increase. Patients who develop this disease usually start experiencing symptoms around age 60 or older. Currently, there's no cure, but scientists are reporting a novel approach that reversed Parkinson's-like symptoms in rats. Their results, published in the journal ACS Nano, could one day lead to a new therapy for human patients. [More]
Blend Therapeutics Announces Presentation of Preclinical Data on Lead Pentarin Program, BTP-277

Blend Therapeutics Announces Presentation of Preclinical Data on Lead Pentarin Program, BTP-277

Blend Therapeutics, Inc., a biopharmaceutical company discovering and developing two distinct classes of targeted anti-cancer medicines to advance the treatment of patients with solid tumor cancers, presented preclinical data today on its lead Pentarin™ program, BTP-277, showing specific and potent targeting of tumor cells expressing the somatostatin receptor, which is known to be over expressed in small cell lung cancer (SCLC) and neuroendocrine cancer tumor cells. [More]
Oasmia's Paclical Nanoparticle Cancer Drug with Paclitaxel Receives Russian Health Ministry Market Authorization

Oasmia's Paclical Nanoparticle Cancer Drug with Paclitaxel Receives Russian Health Ministry Market Authorization

Oasmia Pharmaceutical AB ("Oasmia") announced today that its lead cancer product Paclical received market authorization in the Russian Federation by the Russian Ministry of Health. Paclical is the first water-soluble cancer drug with paclitaxel to receive a market authorization. Paclical is planned for launch in the second half of 2015. [More]
Anti-Herpes Nanoviricides Reduce Extent of Disease and Mortality of HSV-1 Infected Animals

Anti-Herpes Nanoviricides Reduce Extent of Disease and Mortality of HSV-1 Infected Animals

NanoViricides, Inc., (the "Company"), a nanomedicine company developing anti-viral drugs, reports dramatic improvement in clinical symptoms associated with herpes simplex virus infection in the recently completed studies in mice. The studies were performed in the laboratory of Dr. Ken S. Rosenthal at Northeast Ohio Medical University where Dr. Rosenthal is now Professor Emeritus. He is a leading researcher in herpes virus anti-viral agents and vaccines. [More]